Search results for "Color"

showing 10 items of 2721 documents

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 ove…

2018

At the histological level, tumor budding in colon cancer is the result of cells undergoing at least partial epithelial-to-mesenchymal transition. The microRNA 200 family is an important epigenetic driver of this process, mainly by downregulating zinc-finger E-box binding homeobox (ZEB) and transforming growth factor beta (TGF-β) expression. We retrospectively explored the expression of the miR200 family, and ZEB1 and ZEB2, and their relationship with immune resistance mediated through PD-L1 overexpression. For this purpose, we analyzed a series of 125 colon cancer cases and took samples from two different tumor sites: the area of tumor budding at the invasive front and from the tumor center…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyEpithelial-Mesenchymal TransitionColorectal cancerPD-L1 OverexpressionBiologyB7-H1 AntigenPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineTumor buddingmicroRNAmedicineHumansAgedRetrospective StudiesAged 80 and overBuddingMesenchymal stem cellTransforming growth factor betaMiddle Agedmedicine.disease3. Good healthMicroRNAs030104 developmental biology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchbiology.proteinBiomarker (medicine)FemaleModern Pathology
researchProduct

A Phase I Study of Cisplatinum plus 5-Fluorouracil in Modulation with Citrovorum Factor in Metastatic Colorectal Carcinoma

1991

A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil. The first group of patients received cisplatin at the dose of 5 mg/m2/week. Cisplatin was then escalated to 10, 15, 20, 25, 30, and 35 mg/m2/week for subsequent groups of patients. Gastrointestinal side-effects were the dose-limiting toxicity. A therapy related death was seen at the dose of 35 mg/m2/week of cisplatin. The maximally tolerated dose of cisplatin in combination with 5-fluorouracil and citrovorum factor is 20 mg/m2/week. The…

AdultMale0301 basic medicinemedicine.medical_specialtyColorectal cancer030106 microbiologyLeucovorinPhases of clinical researchRectumGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedPharmacologyCisplatinbusiness.industryCarcinomaRemission InductionMiddle Agedmedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracil030220 oncology & carcinogenesisToxicityDrug EvaluationFemaleFluorouracilCisplatinColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct

The effect of longitudinal chromatic aberration on the lag of accommodation and depth of field.

2016

Purpose Longitudinal chromatic aberration is present in all states of accommodation and may play a role in the accommodation response and the emmetropisation process. We study the change of the depth of field (DOFi) with the state of accommodation, taking into account the longitudinal chromatic aberration. Methods Subjective DOFi was defined as the range of defocus beyond which the blur of the target (one line of optotypes of 0.1 logMAR shown on a black-and-white microdisplay, seen through different colour filters) was perceived as objectionable. The subject's eye was paralysed and different, previously-measured accommodative states (corresponding to the accommodative demands of 0D, 2D and …

AdultMaleAccommodative responseLag01 natural sciencesDeformable mirror010309 optics03 medical and health sciencesYoung Adult0302 clinical medicineOpticsPhysiological optics0103 physical sciencesChromatic aberrationHumansDepth of fieldMathematicsDepth Perceptionbusiness.industryAccommodation OcularEmmetropiaSensory SystemsOphthalmology030221 ophthalmology & optometryOptometryFemaleMonochromatic colorbusinessAccommodationColor PerceptionPhotic StimulationOptometryOphthalmicphysiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
researchProduct

Mutation spectrum and clinical investigation of achromatopsia patients with mutations in the GNAT2 gene

2019

Achromatopsia (ACHM) is a hereditary cone photoreceptor disorder characterized by the inability to discriminate colors, nystagmus, photophobia, and low-visual acuity. Six genes have been associated with this rare autosomal recessively inherited disease, including the GNAT2 gene encoding the catalytic α-subunit of the G-protein transducin which is expressed in the cone photoreceptor outer segment. Out of a cohort of 1,116 independent families diagnosed with a primary clinical diagnosis of ACHM, we identified 23 patients with ACHM from 19 independent families with likely causative mutations in GNAT2, representing 1.7% of our large ACHM cohort. In total 22 different potentially disease-causing…

AdultMaleAchromatopsiagenetic structuresAdolescentChild preschoolDNA Copy Number VariationsColor Vision DefectsBiologymedicine.disease_causeHeterotrimeric GTP-Binding Proteins/genetics03 medical and health sciencesExonGene duplicationGeneticsmedicineHumansGenetic Predisposition to DiseaseCopy-number variationColor Vision Defects/geneticsChildGenetics (clinical)030304 developmental biologyAgedGenetics0303 health sciencesGNAT2MutationSettore MED/30 - Malattie Apparato Visivo030305 genetics & heredityBreakpointInfantSequence Analysis DNAExonsMiddle Agedmedicine.diseaseHeterotrimeric GTP-Binding ProteinsPhotoreceptor outer segmenteye diseasesPedigreeSettore BIO/18 - GeneticaSequence Analysis DNA/methodsyoung adultFemalesense organsachromatopsia copy number variations GNAT2 mutations transducinmutation
researchProduct

Prismatic lenses shift time perception

2009

Previous studies have demonstrated the involvement of spatial codes in the representation of time and numbers. We took advantage of a well-known spatial modulation (prismatic adaptation) to test the hypothesis that the representation of time is spatially oriented from left to right, with smaller time intervals being represented to the left of larger time intervals. Healthy subjects performed a time-reproduction task and a time-bisection task, before and after leftward and rightward prismatic adaptation. Results showed that prismatic adaptation inducing a rightward orientation of spatial attention produced an overestimation of time intervals, whereas prismatic adaptation inducing a leftward…

AdultMaleAdolescentColor visionmedia_common.quotation_subjectPoison controlAdaptation (eye)Young AdultDiscrimination PsychologicalPerceptionOrientationSPACEHumansAttentionTime processingGeneral Psychologymedia_commonPerceptual DistortionSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaOrientation (computer vision)business.industryAdaptation OcularPattern recognitionTime perceptionShift timeTIMEMemory Short-TermPattern Recognition VisualTime PerceptionFemaleArtificial intelligenceSensory DeprivationPsychologybusinessColor PerceptionPsychomotor Performance
researchProduct

Spectral Transmission of the Human Crystalline Lens in Adult and Elderly Persons: Color and Total Transmission of Visible Light

2012

Purpose To experimentally measure the spectral transmission of human crystalline lenses belonging to adult and elderly persons, and to determine the color and total transmission of visible light of such crystalline lenses. Methods The spectral transmission curve of 32 human crystalline lenses was measured using a PerkinElmer 800UV/VIS spectrometer. Total transmission of visible light and the chromatic coordinates of these crystalline lenses were determined from these curves for solar illumination. Results The crystalline lens that filters UV and its transmission in the visible spectrum decreases with age; such a decrease is greater for short wavelengths. The total transmission of visible li…

AdultMaleAgingMaterials scienceUltraviolet RaysColorMineralogylaw.inventionOpticsElderly personslawLens CrystallineTransmittanceHumansChromatic scaleAgedSunlightSpectrometerbusiness.industrySpectrum AnalysisMiddle Agedeye diseasesLens (optics)WavelengthSunlightFemalesense organsbusinessPhotic StimulationVisible spectrumInvestigative Opthalmology & Visual Science
researchProduct

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Ita…

2005

Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previou…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyLung NeoplasmsOrganoplatinum CompoundsColorectal cancerPhases of clinical researchAntineoplastic AgentsToxicologyDeoxycytidineGastroenterologyDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)CapecitabinePeritoneal NeoplasmsAgedAged 80 and overPharmacologyPerformance statusbusiness.industryCarcinomaLiver NeoplasmsMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenItalyOncologyFluorouracilLymphatic MetastasisFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-ho…

2001

Summary Background There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic colorectal cancer using palliative chemotherapy. The object of this study was to examine the diagnostic accuracy of monitoring of palliative chemotherapy by means of CEA and CA19-9. Patients and methods The tumour markers CEA and CA 19-9 were subjected to serial measurement in patients with metastatic colorectal cancer (n = 90) using palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-FU with FA and were compared with objective response according to WHO criteria. 85 patients could be evaluated. 43 patients (51%) initially had elevated…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPalliative careCA-19-9 AntigenColorectal cancerLeucovorinSensitivity and SpecificityGastroenterologyDrug Administration ScheduleFolinic acidCarcinoembryonic antigenRecurrenceInternal medicinemedicineHumansInfusions IntravenousAgedTumor markerbiologybusiness.industryPalliative CareHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCarcinoembryonic AntigenSurgeryOncologyFluorouracilbiology.proteinFemaleCA19-9FluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A Bayesian Method for Predicting 5‐Fluorouracil Pharmacokinetic Parameters Following Short‐Term Infusion in Patients With Colorectal Cancer

2003

Abstract The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori , the individual volume of distribution ( V d ) and clearance ( Cl ) of 5‐fluorouracil (5‐FU) given as short‐term intravenous infusion in weekly and multiple doses. Forty‐four patients were divided in group A (5‐FU weekly doses) including 27 patients with nonmetastatic colorectal adenocarcinoma treated with 450 mg/m 2 of 5‐FU, 1 day per week for 48 doses, plus oral levamisol (50 mg/8 h) for 3 days, every 15 days and group B (5‐FU multiple doses) including 17 patients with metastatic colorectal adenocarcinoma, receiving 5‐F…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPopulationUrologyPharmaceutical ScienceRenal functionModels BiologicalDrug Administration ScheduleFolinic acidPharmacokineticsInternal medicineBlood plasmamedicineHumansInfusions IntravenouseducationAgedBody surface areaVolume of distributioneducation.field_of_studybusiness.industryBayes TheoremMiddle AgedNONMEMEndocrinologyArea Under CurveFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome)

1999

The genetic mucopolysaccharidosis syndromes (MPS) are autosomal recessive inborn errors of metabolism. Heart valve involvement in MPS is not uncommon but only a few case reports of successful cardiac surgery are available. In particular, reports of combined aortic and mitral stenosis associated with MPS type I-S are very rare. Both type I and type VI MPS are associated with significant left sided valvar heart disease that requires surgical valve replacement because of irregular valve thickening, fibrosis, and calcification. A 35 year old man had severe mitral valve stenosis after successful surgical replacement of a stenotic aortic valve. Valvar heart disease was investigated by cardiac ult…

AdultMaleAortic valvecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis Imedicine.medical_treatmentCase ReportMitral valve stenosisValve replacementMitral valveInternal medicineMucopolysaccharidosis IHumansMitral Valve StenosisMedicinecardiovascular diseasesHeart valvebusiness.industrynutritional and metabolic diseasesAortic Valve Stenosismedicine.diseaseEchocardiography Doppler ColorCardiac surgerySurgerymedicine.anatomical_structureEchocardiographyAortic valve stenosiscardiovascular systemCardiologyMitral ValveCardiology and Cardiovascular MedicinebusinessHeart
researchProduct